Advancements in Pharmacogenomics for Precision Medicine
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".
Deadline for manuscript submissions: 20 June 2026 | Viewed by 7
Special Issue Editor
2. Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain
Interests: precision; predictive medicine; pharmacogenomics; pharmacoepigenomics
Special Issue Information
Dear Colleagues,
Background: Pharmacogenomics—the study of how genetic variations influence drug metabolism, efficacy, and toxicity—plays a pivotal role in the evolution of precision medicine. Advances in genomic sequencing, computational biology, and data analytics have enabled clinicians and researchers to better understand interindividual variability in drug response.
Aim and scope: This Special Issue of Genes, “Advancements in Pharmacogenomics for Precision Medicine,” aims to showcase the latest discoveries and applications that integrate pharmacogenomic and pharmacoepigenomic knowledge into clinical and translational settings. The Special Issue seeks to bridge basic research, clinical implementation, and policy development to accelerate personalized healthcare.
History: Over the past two decades, pharmacogenomics has transitioned from a research niche to a key component of precision medicine. Landmark findings in pharmacogenes such as CYP450, TPMT, UGT1A1, and SLCO1B1 have laid the groundwork for genomic-guided therapies across multiple therapeutic areas. More recently, the emergence of pharmacoepigenomics has expanded this field by revealing how epigenetic mechanisms—such as DNA methylation and histone modification—modulate drug response beyond genetic variation. In addition, these epigenetic modifications can also be modified by a novel class of treatments (i.e., epidrugs), such as HDAC or HAT inhibitors/activators, for example.
Cutting-edge research: We highlight innovations in multi-omics integration, artificial intelligence for pharmacogenomic prediction, population-specific studies, and real-world clinical implementations of pharmacogenomic testing.
What kind of papers we are soliciting: We invite original research articles, comprehensive reviews, and methodological or perspective papers focusing on novel biomarkers, clinical translation, regulatory and ethical aspects, and strategies to integrate pharmacogenomics into routine medical care.
Dr. Óscar Teijido Hermida
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacogenomics
- precision medicine
- pharmacoepigenomics
- epidrugs
- genomic biomarkers
- drug response variability
- personalized therapy
- multi-omics integration
- pharmacogenetic testing
- clinical implementation
- artificial intelligence in pharmacogenomics
- genetic polymorphisms
- translational genomics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
